Affymetrix (AFFX) 8.01 $AFFX
Will Patterson (PDCO) Disappoint this Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon May 12, 12:00PM CDT
Patterson's (PDCO) bottom-line growth was on par with the Zacks Consensus Estimate.
Q1 Loss Wider than Expected at Genomic Health - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri May 09, 2:30PM CDT
Following the disappointing earnings performance, Genomic Health's share price declined 1.5% on May 8.
Myriad Genetics Drops despite Earnings, Revs Beat; Ups View - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu May 08, 2:00PM CDT
Myriad Genetics (MYGN) reported EPS of 60 cents in the third quarter of fiscal 2014.
Affymetrix and Leica Biosystems Announce the Launch of Fully Automated RNA in situ Hybridization Assays
Business Wire - Thu May 08, 4:30AM CDT
Affymetrix, Inc. (NASDAQ:AFFX) and Leica Biosystems announce the launch of Affymetrix' fully automated RNA in situ hybridization assays ViewRNA(TM) eZ Assays on the Leica BOND RX staining platform. These assays detect coding RNA as well as novel non-coding markers in formalin-fixed paraffin-embedded (FFPE) tissues. Dedicated for research use only*, the assays provide researchers with a powerful automated solution for drug discovery, translational research, and the development of new diagnostic tests for personalized medicine. The automation significantly reduces hands-on time and assay run time for profiling single-cell gene expression.
Global Flow Cytometry (Reagents, Instruments, Software, & Accessories) Market - Global Forecasts to 2018
M2 - Wed May 07, 11:12AM CDT
Research and Markets (http://www.researchandmarkets.com/research/38ct22/flow_cytometry) has announced the addition of the "Flow Cytometry Market by Technology, Products & Services, Application, End User - Global Forecasts to 2018" report to their offering. On the basis of products, the global flow cytometry market has been segmented into instruments, reagents and consumables, software, services, and accessories. In 2013, the reagents and consumables segment accounted for the largest share of 45%in the global market, and is also expected to grow at the highest CAGR of 11.2% from 2013 to 2018. In addition, the global market is classified into three segments based on the type of technology, namely, cell-based, bead-based, and others. The cell-based segment accounted for the largest share of 80% in the global market In the report, the global market is further segmented on the basis of type of end users, which includes commercial organizations, hospitals, academic institutions, medical schools, and clinical testing labs. In 2013, the commercial organization segment accounted for the largest share of 35% in the market. Likewise, based on the type of applications, the global market is classified into three categories, namely, research, clinical, and industrial applications. Application of flow cytometry in the research fields commands the major chunk of the market in 2013. Key Topics Covered: 1 Introduction 2 Executive Summary 3 Premium Insights 4 Market Overview 5 Industry Trends 6 Global Flow Cytometry Market, By Technology 7 Global Flow Cytometry Market, By Product 8 Flow Cytometry Market, By Application 9 Flow Cytometry Market, By End User 10 Global Flow Cytometry Market, By Geography 11 Competitive Landscape 12 Company Profiles Companies Mentioned: - Beckman Coulter, Inc. (A Subsidiary Of Danaher Corporation) - Becton, Dickinson And Company - Bio-Rad Laboratories, Inc. - Ebioscience, Inc. (A Subsidiary Of Affymetrix, Inc.) - Emd Millipore Corporation (A Division Of Merck Kgaa) - Life Technologies Corporation (A Brand Of Thermo Fisher Scientific, Inc.) - Luminex Corporation - Miltenyi Biotech - Partec Gmbh - Ttp Labtech Ltd. For more information visit http://www.researchandmarkets.com/research/38..._cytometry
Quarterly Results Releases and Strategic Acquisitions - Analyst Notes on Waters, Allegion, Curtiss-Wright, FARO and Affymetrix
PR Newswire - Tue May 06, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Waters Corp. (NYSE: WAT), Allegion plc (NYSE: ALLE), Curtiss-Wright Corp. (NYSE: CW), FARO Technologies Inc. (NASDAQ: FARO) and Affymetrix Inc. (NASDAQ: AFFX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2059-100free.
Affymetrix Q1 Earnings Beat Ests by a Penny - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri May 02, 1:50PM CDT
Affymetrix Inc. (AFFX) reaffirmed its previously announced revenue and EBITDA guidance for 2014.
Affymetrix Reports First Quarter 2014 Operating Results
Business Wire - Thu May 01, 3:01PM CDT
Affymetrix, Inc., (NASDAQ: AFFX) today reported its operating results for the first quarter of 2014.
Global Gene Expression Market Technology, Consumables, Services & Applications Report 2014-2019
M2 - Thu May 01, 4:09AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5nrjl2/gene_expression) has announced the addition of the "Global Gene Expression Market Technology, Consumables, Services & Applications Report 2014-2019" report to their offering. Gene expression analysis has emerged as a major advancement in the fields of drug discovery, diagnostics, and biomedical research. Since the completion of the Human Genome Project in 2003, numerous methods are being developed to improve the efficiency and effectiveness of gene expression profiling and sequencing. it is an important process, as it enables researchers to decipher the functions of genes. By sequencing genes, researchers can determine how diseases affect a cell. Genome-wide analysis can be used to accurately classify diseases. This has led to its increased use in various applications such as pharmacogenomics, diagnostics, toxicogenomics, and biomarkers. The global market was valued at $2.6 billion in 2013 and is expected to reach $4.3 billion by 2018, at a CAGR of 10.4%. Increasing number of cancer patients, growth in the number of funding activities, technological advancements, and increased interest in gene expression for research and discovery are the major factors driving the growth of this market. Moreover, various government bodies have extended their help in the form of investments, funds, and grants, which has further stimulated the growth of the market. Life Technologies (U.S.), QIAGEN N.V. (Netherlands), Illumina, Inc. (U.S.), Roche Diagnostics (Switzerland), Bio-Rad Laboratories, Inc. (U.S.), Agilent Technologies (U.S.), Affymetrix, Inc. (U.S.), GE Healthcare (U.K.), Thermo Fisher Scientific (U.S.), PerkinElmer, Inc. (U.S.), Luminex Corporation (U.S.), and Oxford Gene Technology, Inc. (U.K.) are some of the prominent players in the global market. Key Topics Covered: 1 Introduction 2 Executive Summary 3 Market Overview - Increasing Number Of Cancer Patients Globally - Increase In Investments, Funds, And Grants By Government Bodies Worldwide - Technological Advancements - Small Rnas Gaining Momentum - Gene Expression Databases To Aid Cancer Research - Use Of Microarray Technology To Aid Gene Expression Studies - Use Of Sbs Technology To Aid More Detailed Cancer Studies - High Cost Of Instruments - Dearth Of Technical Expertise - Rising Opportunities In Emerging Nations - Growth In Personalized Medicine (Gene Therapy) - Sequencing Platforms - Gene Expression Application Market Analysis 4 Gene Expression Analysis Market, By Segment 5 Gene Expression Analysis Instrumentation Market, By Technology - DNA Microarrays - Real-Time Polymerase Chain Reaction (Rt-Pcr) - Next Generation Sequencing - Serial Analysis Of Gene Expression (Sage) - Northern Blotting 6 Gene Expression Analysis Consumables Market, By Product - DNA Chips - Oligonucleotides - CDNA - Reagents 7 Gene Expression Analysis Services Market, By Product - Gene Expression Profiling Services - Bioinfomatics Solutions - Data Analysis Software 8 Gene Expression Analysis Market, By Application - Diagnostics - Drug Discovery - Academic Research - Biomarkers - Others 9 Geographic Analysis 10 Competitive Landscape 11 Company Profiles - Affymetrix, Inc. - Agilent Technologies - Bio-Rad Laboratories, Inc. - Ge Healthcare (Subsidiary Of General Electric Company) - Illumina, Inc. - Life Technologies - Luminex Corporation - Oxford Gene Technology, Inc. - Perkinelmer, Inc. - Qiagen N.V. - Roche Diagnostics Corporation For more information visit http://www.researchandmarkets.com/research/5n...expression
Is a Surprise Coming for Affymetrix (AFFX) This Earnings Season? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Apr 30, 7:36AM CDT
Affymetrix has been witnessing a significant price rise in the past month with a positive momentum in the earnings estimate front
Can Affymetrix (AFFX) Surprise This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 29, 5:25PM CDT
Affymetrix (AFFX) had delivered positive earnings surprises in 2 of its last 4 quarters, with an impressive average beat of 192.86%.
RadNet (RDNT) Catches Eye: Stock Rises 6.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Apr 29, 8:46AM CDT
RadNet (RDNT) was a big mover last session, with shares rising over 6% on the day.
Can Becton, Dickinson (BDX) Keep the Earnings Streak Alive? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 28, 2:10PM CDT
Becton, Dickinson (BDX) reported adjusted earnings of $1.42 per share, beating the Zacks Consensus Estimate by 13 cents.
Global Enteric Disease Testing Market 2014-2018: Alere, bioMerieux, Bio-Rad Laboratories, Cepheid & DiaSorin Dominate the Market
M2 - Mon Apr 28, 11:25AM CDT
Research and Markets (http://www.researchandmarkets.com/research/s27mxj/global_enteric) has announced the addition of the "Global Enteric Disease Testing Market 2014-2018: Alere, bioM?rieux, Bio-Rad Laboratories, Cepheid & DiaSorin Dominate the Market" report to their offering. One of the major drivers in the market is the increasing incidence of enteric diseases among the population, creating a need for testing methods that effectively diagnose diseases. The discovery and characterization of new emerging viruses and bacteria is playing an important role in the Diagnostics industry. Vendors are introducing new diagnostic tests for new found pathogens that are responsible for some other types of infectious diseases. These new pathogens include West Nile virus, respiratory syncytial virus, genital mycoplasma, C. difficile, norovirus, and rotavirus. C. difficile and rotavirus tests have seen the maximum level of acceptance in the market. Thus, the improvement in detection technology aiding in the identification of new pathogens is driving the need for enteric disease testing products. Further, the report states that one of the major challenges in the market is the presence of stringent regulatory approval processes for clinical in-vitro diagnostic tests for enteric disease identification. Key vendors dominating this space are: - Alere Inc - bioM?rieux SA - Bio-Rad Laboratories Inc. - Cepheid Inc. - DiaSorin S.p.A. Other vendors mentioned in the report are: - Affymetrix Inc. - Beckton, Dickenson and Co - Biomerica Inc - Coris BioConcept - Danaher Corp. - Meridian Bioscience Inc. - Quest Diagnostics Inc. - R-Biopharm AG - Trinity Biotech PLC. Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Market Segmentation by Type of Diseases - Types of Clinical Diagnostic Testing - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/s2...al_enteric
Can Cardinal Health (CAH) Keep the Earnings Streak Alive? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 25, 5:30PM CDT
Cardinal Health (CAH) reported adjusted earnings of 90 cents per share, beating the Zacks Consensus Estimate by 8.4%.
Enzo Biochem signs USD5.1m litigation settlement agreement with Affymetrix
M2 - Fri Apr 25, 6:16AM CDT
Molecular diagnostics company Enzo Biochem (NYSE:ENZ) and its subsidiary Enzo Life Sciences jointly announced on Thursday a favourable litigation settlement agreement with Affymetrix (NasdaqGS:AFFX) in the US District Court, Southern District of New York.
Enzo Biochem Announces Settlement Agreement with Affymetrix
Business Wire - Thu Apr 24, 8:45AM CDT
Enzo Biochem, Inc. (NYSE:ENZ) (the "Company"
, along with its subsidiary Enzo Life Sciences, Inc. entered into a Settlement with Affymetrix, Inc. (NASDAQ:AFFX) with respect to actions between the Company and Affymetrix before the U.S. District Court, Southern District of New York, Cases No 03-CV-8907 and 04-CV-1555.
Can Varian Medical Systems (VAR) Surprise This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 23, 4:21PM CDT
Varian's (VAR) earnings rose 5.8% year over year to 91 cents per share in the last reported quarter, exceeding the Zacks Consensus Estimate by a penny.
Can Stryker (SYK) Surprise This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 22, 5:15PM CDT
Stryker's earnings increased 7.9% year over year to $1.23 per share in the reported quarter.
CollabRx Partnership with Affymetrix Creates a Foundation
ACCESSWIRE - Tue Apr 22, 10:05AM CDT
WHITEFISH, MT / April 22, 2014 / Foundation Medicine Inc. (NYSE: FMI) made headlines in September 2013 with a well received $106 million IPO and a 78% first-day jump in share price. Despite lackluster demand for diagnostics stocks in general, investors jumped at the opportunity to invest in the company's unique approach of determining, in a single test of a cancer patient's tumor, whether any genetic mutations are present in literally hundreds of genes that can be paired with therapies that target those specific mutations.
Will Patterson (PDCO) Disappoint this Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon May 12, 12:00PM CDT
Patterson's (PDCO) bottom-line growth was on par with the Zacks Consensus Estimate.
Q1 Loss Wider than Expected at Genomic Health - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri May 09, 2:30PM CDT
Following the disappointing earnings performance, Genomic Health's share price declined 1.5% on May 8.
Myriad Genetics Drops despite Earnings, Revs Beat; Ups View - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu May 08, 2:00PM CDT
Myriad Genetics (MYGN) reported EPS of 60 cents in the third quarter of fiscal 2014.
Affymetrix and Leica Biosystems Announce the Launch of Fully Automated RNA in situ Hybridization Assays
Business Wire - Thu May 08, 4:30AM CDT
Affymetrix, Inc. (NASDAQ:AFFX) and Leica Biosystems announce the launch of Affymetrix' fully automated RNA in situ hybridization assays ViewRNA(TM) eZ Assays on the Leica BOND RX staining platform. These assays detect coding RNA as well as novel non-coding markers in formalin-fixed paraffin-embedded (FFPE) tissues. Dedicated for research use only*, the assays provide researchers with a powerful automated solution for drug discovery, translational research, and the development of new diagnostic tests for personalized medicine. The automation significantly reduces hands-on time and assay run time for profiling single-cell gene expression.
Global Flow Cytometry (Reagents, Instruments, Software, & Accessories) Market - Global Forecasts to 2018
M2 - Wed May 07, 11:12AM CDT
Research and Markets (http://www.researchandmarkets.com/research/38ct22/flow_cytometry) has announced the addition of the "Flow Cytometry Market by Technology, Products & Services, Application, End User - Global Forecasts to 2018" report to their offering. On the basis of products, the global flow cytometry market has been segmented into instruments, reagents and consumables, software, services, and accessories. In 2013, the reagents and consumables segment accounted for the largest share of 45%in the global market, and is also expected to grow at the highest CAGR of 11.2% from 2013 to 2018. In addition, the global market is classified into three segments based on the type of technology, namely, cell-based, bead-based, and others. The cell-based segment accounted for the largest share of 80% in the global market In the report, the global market is further segmented on the basis of type of end users, which includes commercial organizations, hospitals, academic institutions, medical schools, and clinical testing labs. In 2013, the commercial organization segment accounted for the largest share of 35% in the market. Likewise, based on the type of applications, the global market is classified into three categories, namely, research, clinical, and industrial applications. Application of flow cytometry in the research fields commands the major chunk of the market in 2013. Key Topics Covered: 1 Introduction 2 Executive Summary 3 Premium Insights 4 Market Overview 5 Industry Trends 6 Global Flow Cytometry Market, By Technology 7 Global Flow Cytometry Market, By Product 8 Flow Cytometry Market, By Application 9 Flow Cytometry Market, By End User 10 Global Flow Cytometry Market, By Geography 11 Competitive Landscape 12 Company Profiles Companies Mentioned: - Beckman Coulter, Inc. (A Subsidiary Of Danaher Corporation) - Becton, Dickinson And Company - Bio-Rad Laboratories, Inc. - Ebioscience, Inc. (A Subsidiary Of Affymetrix, Inc.) - Emd Millipore Corporation (A Division Of Merck Kgaa) - Life Technologies Corporation (A Brand Of Thermo Fisher Scientific, Inc.) - Luminex Corporation - Miltenyi Biotech - Partec Gmbh - Ttp Labtech Ltd. For more information visit http://www.researchandmarkets.com/research/38..._cytometry
Quarterly Results Releases and Strategic Acquisitions - Analyst Notes on Waters, Allegion, Curtiss-Wright, FARO and Affymetrix
PR Newswire - Tue May 06, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Waters Corp. (NYSE: WAT), Allegion plc (NYSE: ALLE), Curtiss-Wright Corp. (NYSE: CW), FARO Technologies Inc. (NASDAQ: FARO) and Affymetrix Inc. (NASDAQ: AFFX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2059-100free.
Affymetrix Q1 Earnings Beat Ests by a Penny - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri May 02, 1:50PM CDT
Affymetrix Inc. (AFFX) reaffirmed its previously announced revenue and EBITDA guidance for 2014.
Affymetrix Reports First Quarter 2014 Operating Results
Business Wire - Thu May 01, 3:01PM CDT
Affymetrix, Inc., (NASDAQ: AFFX) today reported its operating results for the first quarter of 2014.
Global Gene Expression Market Technology, Consumables, Services & Applications Report 2014-2019
M2 - Thu May 01, 4:09AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5nrjl2/gene_expression) has announced the addition of the "Global Gene Expression Market Technology, Consumables, Services & Applications Report 2014-2019" report to their offering. Gene expression analysis has emerged as a major advancement in the fields of drug discovery, diagnostics, and biomedical research. Since the completion of the Human Genome Project in 2003, numerous methods are being developed to improve the efficiency and effectiveness of gene expression profiling and sequencing. it is an important process, as it enables researchers to decipher the functions of genes. By sequencing genes, researchers can determine how diseases affect a cell. Genome-wide analysis can be used to accurately classify diseases. This has led to its increased use in various applications such as pharmacogenomics, diagnostics, toxicogenomics, and biomarkers. The global market was valued at $2.6 billion in 2013 and is expected to reach $4.3 billion by 2018, at a CAGR of 10.4%. Increasing number of cancer patients, growth in the number of funding activities, technological advancements, and increased interest in gene expression for research and discovery are the major factors driving the growth of this market. Moreover, various government bodies have extended their help in the form of investments, funds, and grants, which has further stimulated the growth of the market. Life Technologies (U.S.), QIAGEN N.V. (Netherlands), Illumina, Inc. (U.S.), Roche Diagnostics (Switzerland), Bio-Rad Laboratories, Inc. (U.S.), Agilent Technologies (U.S.), Affymetrix, Inc. (U.S.), GE Healthcare (U.K.), Thermo Fisher Scientific (U.S.), PerkinElmer, Inc. (U.S.), Luminex Corporation (U.S.), and Oxford Gene Technology, Inc. (U.K.) are some of the prominent players in the global market. Key Topics Covered: 1 Introduction 2 Executive Summary 3 Market Overview - Increasing Number Of Cancer Patients Globally - Increase In Investments, Funds, And Grants By Government Bodies Worldwide - Technological Advancements - Small Rnas Gaining Momentum - Gene Expression Databases To Aid Cancer Research - Use Of Microarray Technology To Aid Gene Expression Studies - Use Of Sbs Technology To Aid More Detailed Cancer Studies - High Cost Of Instruments - Dearth Of Technical Expertise - Rising Opportunities In Emerging Nations - Growth In Personalized Medicine (Gene Therapy) - Sequencing Platforms - Gene Expression Application Market Analysis 4 Gene Expression Analysis Market, By Segment 5 Gene Expression Analysis Instrumentation Market, By Technology - DNA Microarrays - Real-Time Polymerase Chain Reaction (Rt-Pcr) - Next Generation Sequencing - Serial Analysis Of Gene Expression (Sage) - Northern Blotting 6 Gene Expression Analysis Consumables Market, By Product - DNA Chips - Oligonucleotides - CDNA - Reagents 7 Gene Expression Analysis Services Market, By Product - Gene Expression Profiling Services - Bioinfomatics Solutions - Data Analysis Software 8 Gene Expression Analysis Market, By Application - Diagnostics - Drug Discovery - Academic Research - Biomarkers - Others 9 Geographic Analysis 10 Competitive Landscape 11 Company Profiles - Affymetrix, Inc. - Agilent Technologies - Bio-Rad Laboratories, Inc. - Ge Healthcare (Subsidiary Of General Electric Company) - Illumina, Inc. - Life Technologies - Luminex Corporation - Oxford Gene Technology, Inc. - Perkinelmer, Inc. - Qiagen N.V. - Roche Diagnostics Corporation For more information visit http://www.researchandmarkets.com/research/5n...expression
Is a Surprise Coming for Affymetrix (AFFX) This Earnings Season? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Apr 30, 7:36AM CDT
Affymetrix has been witnessing a significant price rise in the past month with a positive momentum in the earnings estimate front
Can Affymetrix (AFFX) Surprise This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 29, 5:25PM CDT
Affymetrix (AFFX) had delivered positive earnings surprises in 2 of its last 4 quarters, with an impressive average beat of 192.86%.
RadNet (RDNT) Catches Eye: Stock Rises 6.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Apr 29, 8:46AM CDT
RadNet (RDNT) was a big mover last session, with shares rising over 6% on the day.
Can Becton, Dickinson (BDX) Keep the Earnings Streak Alive? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 28, 2:10PM CDT
Becton, Dickinson (BDX) reported adjusted earnings of $1.42 per share, beating the Zacks Consensus Estimate by 13 cents.
Global Enteric Disease Testing Market 2014-2018: Alere, bioMerieux, Bio-Rad Laboratories, Cepheid & DiaSorin Dominate the Market
M2 - Mon Apr 28, 11:25AM CDT
Research and Markets (http://www.researchandmarkets.com/research/s27mxj/global_enteric) has announced the addition of the "Global Enteric Disease Testing Market 2014-2018: Alere, bioM?rieux, Bio-Rad Laboratories, Cepheid & DiaSorin Dominate the Market" report to their offering. One of the major drivers in the market is the increasing incidence of enteric diseases among the population, creating a need for testing methods that effectively diagnose diseases. The discovery and characterization of new emerging viruses and bacteria is playing an important role in the Diagnostics industry. Vendors are introducing new diagnostic tests for new found pathogens that are responsible for some other types of infectious diseases. These new pathogens include West Nile virus, respiratory syncytial virus, genital mycoplasma, C. difficile, norovirus, and rotavirus. C. difficile and rotavirus tests have seen the maximum level of acceptance in the market. Thus, the improvement in detection technology aiding in the identification of new pathogens is driving the need for enteric disease testing products. Further, the report states that one of the major challenges in the market is the presence of stringent regulatory approval processes for clinical in-vitro diagnostic tests for enteric disease identification. Key vendors dominating this space are: - Alere Inc - bioM?rieux SA - Bio-Rad Laboratories Inc. - Cepheid Inc. - DiaSorin S.p.A. Other vendors mentioned in the report are: - Affymetrix Inc. - Beckton, Dickenson and Co - Biomerica Inc - Coris BioConcept - Danaher Corp. - Meridian Bioscience Inc. - Quest Diagnostics Inc. - R-Biopharm AG - Trinity Biotech PLC. Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Market Segmentation by Type of Diseases - Types of Clinical Diagnostic Testing - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/s2...al_enteric
Can Cardinal Health (CAH) Keep the Earnings Streak Alive? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 25, 5:30PM CDT
Cardinal Health (CAH) reported adjusted earnings of 90 cents per share, beating the Zacks Consensus Estimate by 8.4%.
Enzo Biochem signs USD5.1m litigation settlement agreement with Affymetrix
M2 - Fri Apr 25, 6:16AM CDT
Molecular diagnostics company Enzo Biochem (NYSE:ENZ) and its subsidiary Enzo Life Sciences jointly announced on Thursday a favourable litigation settlement agreement with Affymetrix (NasdaqGS:AFFX) in the US District Court, Southern District of New York.
Enzo Biochem Announces Settlement Agreement with Affymetrix
Business Wire - Thu Apr 24, 8:45AM CDT
Enzo Biochem, Inc. (NYSE:ENZ) (the "Company"
, along with its subsidiary Enzo Life Sciences, Inc. entered into a Settlement with Affymetrix, Inc. (NASDAQ:AFFX) with respect to actions between the Company and Affymetrix before the U.S. District Court, Southern District of New York, Cases No 03-CV-8907 and 04-CV-1555. Can Varian Medical Systems (VAR) Surprise This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 23, 4:21PM CDT
Varian's (VAR) earnings rose 5.8% year over year to 91 cents per share in the last reported quarter, exceeding the Zacks Consensus Estimate by a penny.
Can Stryker (SYK) Surprise This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 22, 5:15PM CDT
Stryker's earnings increased 7.9% year over year to $1.23 per share in the reported quarter.
CollabRx Partnership with Affymetrix Creates a Foundation
ACCESSWIRE - Tue Apr 22, 10:05AM CDT
WHITEFISH, MT / April 22, 2014 / Foundation Medicine Inc. (NYSE: FMI) made headlines in September 2013 with a well received $106 million IPO and a 78% first-day jump in share price. Despite lackluster demand for diagnostics stocks in general, investors jumped at the opportunity to invest in the company's unique approach of determining, in a single test of a cancer patient's tumor, whether any genetic mutations are present in literally hundreds of genes that can be paired with therapies that target those specific mutations.
